Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MNA-Doxorubicin in Cutaneous T-cell Lymphoma
NCT02192021Phase 1Completed
- Start
- Mar 2016
- Primary completion
- Nov 2020
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of doxorubicin in cutaneous T-cell lymphoma (CTCL). Primary endpoint: Safety Evaluation at 9 weeks. Started Mar 2016; status: completed.
02
Drugs
doxorubicin
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT02192021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02192021.